Concert Pharmaceuticals, Inc. (CNCE) Misses Q2 EPS by 3c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. WCN
7. SPOT
8. SPY
9. FIX
10. TSCO

Go back to Concert Pharmaceuticals, Inc. (CNCE) Misses Q2 EPS by 3c

Roth Keeps Concert Pharma (CNCE) at Buy; Making Good Progress with Clinical Programs

August 12, 2014 3:23 PM EDT

Roth Capital affirms Concert Pharmaceuticals (Nasdaq: CNCE) at Buy with a target price of $28 following the company's Q2 results.

Concert reported Q2 loss of $0.45 per share versus Roth's estimated loss of $0.47 per share.

Analyst Joseph Pantginis commented, We believe Concert is making good progress on their clinical programs, both in their in-house and partnered programs. The company's R&D expenses are... More